Cheryl Alkon

A 2018 Giants of Cancer Care award winner for Drug Development, Joseph R. Bertino, MD, was an early pioneer in developing the understanding of methotrexate and its administration in cancer. His work has served as a platform for much broader investigation into the optimal use of other cancer agents. Along the way, Bertino has mentored many leaders in oncology and hematology and earned international recognition.

John L. Cameron, MD, is most commonly associated with the refinement of Whipple procedures; these extensive surgical operations became far more successful thanks to his dedication.

Kanti R. Rai, MD, has been a leader in the diagnosis and treatment of chronic lymphocytic leukemia for more than 40 years. He was honored in the Hematologic Malignancies category with a 2017 Giants of Cancer Care® award.

Robert J. Motzer, MD, has been at the forefront of research into renal cell carcinoma for nearly 30 years, with his work contributing to the approval of at least 8 new drugs.

As a trailblazer who helped breast cancer treatment evolve from radical mastectomy to the judicious use of radiation therapy with limited tumor removal, Samuel Hellman, MD, is considered one of the world's premier radiation oncologists.

Daniel D. Von Hoff, MD, is focused on developing more targeted therapies for those with pancreatic and other advanced cancers.

The FDA's approval in March of the first biosimilar drug for the US market has aroused much concern among physicians.

The new Value-Based Payment Modifier program from the Centers for Medicare & Medicaid Services may not be high on the list of concerns for the average oncologist, but its impact could be huge.

In 2014, the amount of medical and other information has only increased, and mobile devices such as smartphones and tablets make it even easier to access that data.

Cancer is challenging in many ways. Trying to contain the costs of disease management may be the biggest challenge of all.

When she first heard about the idea of an onsite dispensing pharmacy, Diane Gerards-Benage wondered if the venture could be successful, given the change in cancer treatments from intravenous to oral methods, and the promise of an automated system to track prescriptions and other procedures

For 18 years, Thomas Whittaker, MD, worked as an independent oncologist and as a physician partner in Central Indiana Cancer Centers, a private practice group of 17 doctors that provided medical and radiation oncology care to patients with cancer.